Journal of Clinical Oncology
Articles in this Issue
Clinical characteristics and long-term outcomes of extreme responders to first line treatment of metastatic prostate cancer.
266 Background: Contemporary trials show that the median overall survival of patients with metastatic prostate cancer is a...
Association of urothelial carcinoma with squamous differentiation with Nectin-4 expression and outcomes with enfortumab vedotin (EV) treatment.
865 Background: The Nectin-4 directed antibody-drug conjugate EV has demonstrated high efficacy in metastatic urothelial c...
Whole genome–based ultrasensitive circulating tumor DNA clearance as a biomarker of exceptional outcomes with enfortumab vedotin and pembrolizumab in urothelial carcinoma: Preliminary real-world results.
866 Background: Circulating tumor DNA (ctDNA) is an emerging biomarker for monitoring treatment response and minimal resid...
SWOG S1602: A phase III randomized trial to evaluate BCG strain differences and priming with intradermal BCG before intravesical therapy for BCG-naïve high-grade non-muscle invasive bladder cancer (NCT #03091660).
LBA629 Background: Whether BCG strain influences clinical efficacy is unclear. BCG shortages and a reliance on a single st...
A pragmatic phase 2 trial of locally ablative therapy in oligo-progressive genitourinary (GU) tumors: LAYOVER
TPS291 Background: Oligoprogressive disease (OPD) may represent an opportunity for locally ablative therapies to provide d...
Trastuzumab deruxtecan (T-DXd) in pretreated patients (pts) with HER2-expressing bladder cancer: Final results from the bladder cancer cohort in Part 1 of DESTINY-PanTumor02 (DP-02).
734 Background: In the DP-02 Part 1 primary analysis, T-DXd showed clinically meaningful antitumor activity in HER2-expres...
Germline platelet polygenic risk score to predict renal cell carcinoma survival via sustained thrombocytosis.
543 Background: Polygenic risk scores (PGS) reflect inherited germline variants fixed from conception and is measured earl...
Prognostic utility of lactate dehydrogenase in patients with metastatic seminoma.
604 Background: Serum tumor markers play an important role in risk classification, prognostication, staging, and monitorin...
Metastasis-directed therapy with or without pembrolizumab for oligometastatic clear cell renal cell carcinoma: Pooled analysis of two prospective single-arm phase II trials.
498 Background: Radiotherapy-based metastasis-directed therapy (MDT) has emerged as a viable treatment paradigm for oligom...
Clinical utility of circulating tumor DNA profiling in patients with metastatic urothelial carcinoma treated with enfortumab vedotin.
798 Background: Enfortumab vedotin (EV) is a key drug for metastatic urothelial carcinoma (mUC). However, no established b...
Vertebral surgery in the management of complex postchemotherapeutic retroperitoneal lymph node dissection (PC-RPLND).
610 Background: The involvement of the skeletal system is rare in patients with metastatic testicular germ cell tumors (mG...
Association of <i>MUTYH</i> mutations with clinical outcomes in metastatic prostate cancer.
83 Background: Identification of novel biomarkers that can better predict treatment outcome and prognosis in metastatic ho...
Adjuvant pembrolizumab plus belzutifan versus pembrolizumab for clear cell renal cell carcinoma (ccRCC): The randomized phase 3 LITESPARK-022 study.
LBA418 Background: Adjuvant pembrolizumab is a standard of care for patients with ccRCC at increased risk of recurrence fo...
Turning the tide in recurrent NSGCT: Retrospective insights into TIP vs non-TIP salvage chemotherapy.
602 Background: Recurrent NSGCT poses a therapeutic challenge and the comparative efficacy data of TIP (Paclitaxel, Ifosfa...
Effect of a one-time sensitive screening intervention on prostate cancer mortality: The STHLM3 randomized trial.
312 Background: Prostate cancer (PCa) screening remains controversial and further results on the long-term benefits and ha...
County-level educational attainment and long-term outcomes in older men with prostate cancer: A SEER-Medicare 2009–2017 study.
327 Background: Educational attainment shapes access, treatment, and survivorship in prostate cancer (PC), yet community-l...
MRI-targeted biopsy with index lesion ipsilateral or bilateral systematic biopsy in prostate cancer: A multicenter, paired, noninferiority, observational trial.
375 Background: Index lesion-focused ipsilateral systematic biopsy (iSB) may potentially replace systematic biopsy (SB) in...
ICON trial: Phase I/II trial of inulin gel in combination with ipilimumab and nivolumab in advanced renal cell.
TPS572 Background: The gut microbiome has been shown to impact the safety and efficacy of immune checkpoint inhibitor (ICI...
Androgen deprivation therapy and radiotherapy with or without cabazitaxel in very-high risk localized prostate cancer: First results of the PEACE-2 randomized phase III trial.
LBA307 Background: Long-term androgen deprivation therapy (ADT) combined with radiotherapy is standard in patients with lo...
ADVANCED-2: Interim efficacy and safety data in BCG-unresponsive participants with high-grade non-muscle invasive bladder cancer.
743 Background: Although patients with Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMI...
LUNAR: Safety and efficacy evaluation of nadofaragene firadenovec instilled into the renal pelvis in subjects with low-grade upper tract urothelial carcinoma—A single-arm, open-label phase 1/2 trial.
TPS906 Background: Recommended treatment options for low-grade upper tract urothelial carcinoma (LG-UTUC) include kidney-s...
Incidence of symptomatic hypoxia in a high-altitude cohort of patients with renal cell carcinoma (RCC) treated with belzutifan.
488 Background: Hypoxia-Inducible Factor (HIF-2α) is a transcription factor that allows for adaptation to environments wit...
Longitudinal assessment of patient-reported quality of life and mental health during active surveillance for low-grade NMIBC.
727 Background: While transurethral resection of bladder tumor (TURBT) remains the gold-standard treatment for non–muscle-...
Gut microbiome (GMB) biomarkers in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair alterations (HRRm) treated with PARP inhibitor (PARPi) therapy.
248 Background: As PARPi redefines treatment for HRRm mCRPC, identifying patients most likely to benefit remains a clinica...
Any regression of tumor (ART) to discriminate improvement in overall survival (OS) in patients with metastatic urothelial carcinoma (mUC) receiving PD1/L1 inhibitors who exhibit stable disease (SD) by RECIST1.1.
653 Background: Response to PD1/L1 inhibitors per RECIST 1.1 or immune-related (ir)-RECIST is associated with improved ove...